By early 2026, FDA had publicly announced enforcement actions against multiple compounded GLP-1 telehealth platforms, and in April 2026 formally proposed removing semaglutide, tirzepatide, and liraglutide from the 503B outsourcing bulks list - with a public comment period running through June 2026
Disclaimer: This article is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment
Ask each program how dose increases are handled, how quickly you can reach a provider with side effects, and whether there is any nutrition or behavior support
The insulin and igf-I pathway in endocrine glands carcinogenesis
"I tried everything for 8 months
For select patients whose response or tolerance benefits from a layered approach, we offer a compounded protocol combining semaglutide and tirzepatide